All In Biotech

Drug Trial Radar · NCT07010575

Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride

Decentralized Study to Assess Patient Treatment Preference Comparing Their Current Standard-of-care Wilson's Disease (WD) Treatment to a New Trientine (TETA) 4HCl Formulation.

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Jul 15, 2025

Primary completion

Dec 18, 2025

Study completion Dec 18, 2025

Sponsor

Lead sponsor
OrphalanIndustry
Sponsor type
Industry
First posted
Jun 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Decentralized study to assess patient reported treatment satisfaction comparing their current standard-of-care Wilson's Disease (WD) treatment with a new once-daily Trientine (TETA) 4HCl formulation.

Conditions

  • Wilson's Disease

Interventions

  • New TETA 4HCl FormulationDrug

    Individual patient doses will depend on the Standard of Care (SOC) therapy at study entry and guided by recommended dosing switch schedule outlined in the study protocol. The dose may subsequently be titrated based on clinical response per the investigator's judgement.

  • Standard of CareDrug

    Patients will be returned to their approved Wilson's Disease SOC therapy (dose and frequency) at study entry as prescribed by their treating Wilson's Disease physician.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess and compare patient preference, convenience and satisfaction between current standard of care treatments for Wilson's Disease and the new TETA 4HCl formulation using patient reported outcome questionnaires.Time frame: From the screening assessment (-28 days to Day 1) to end of study at Week 8
  2. Assess and compare patient preference, convenience and satisfaction between current standard of care treatments for Wilson's Disease and the new TETA 4HCl formulation using patient reported outcome questionnaires.Time frame: From the screening assessment (-28 days to Day 1) to end of study at Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • VCTC

    Hartshorne, Derbyshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.